Search

Alogliptin

Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer.

Dimercaprol

In addition, it has in the past been used for the treatment of Wilson's disease, a genetic disorder in which the body tends to retain copper. … Dimercaprol has toxic potential, and its use may be followed by a variety of adverse effects.

Deuruxolitinib

Deuteration allows the drug to circumvent extensive oxidative metabolism around the cyclopentyl ring, which increases the duration of the pharmacological activity of deuruxolitinib. … [L51083] Alopecia areata is an autoimmune condition that attacks the hair follicles and leads to unpredictable hair loss in the scalp and other areas of the body.

Magnesium malate

Sulfanilamide

Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.

Cabotegravir

Cabotegravir, or GSK1265744, is an HIV-1 integrase inhibitor that is prescribed with the non-nucleoside reverse transcriptase inhibitor, [rilpivirine]. … [A227668,L31193] Cabotegravir was granted FDA approval on 21 January 2021 in combination with rilpivirine to treat HIV-1 infection in virologically suppressed individuals.

Lixisenatide

Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). … It is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763]

Entrectinib

[L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. … [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data.

Gefitinib

Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. … Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer.

Tiagabine

Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. … It is also used in the treatment for panic disorder as are a few other anticonvulsants.